Addition of lapatinib to trastuzumab plus an aromatase inhibitor significantly improves progression-free survival (PFS) in patients with metastatic breast cancer, according to new research.
Original Article: [News] Improved progression-free survival in metastatic breast cancer
NEXT ARTICLE